Compare SYRE & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYRE | NATL |
|---|---|---|
| Founded | 2013 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 2015 | 2023 |
| Metric | SYRE | NATL |
|---|---|---|
| Price | $40.36 | $47.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | ★ $55.57 | $42.28 |
| AVG Volume (30 Days) | 681.3K | ★ 978.7K |
| Earning Date | 05-19-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.98 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | ★ $4,354,000,000.00 |
| Revenue This Year | N/A | $5.99 |
| Revenue Next Year | N/A | $4.53 |
| P/E Ratio | ★ N/A | $22.47 |
| Revenue Growth | N/A | ★ 0.86 |
| 52 Week Low | $10.91 | $22.30 |
| 52 Week High | $45.76 | $48.40 |
| Indicator | SYRE | NATL |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 76.59 |
| Support Level | $14.62 | $35.19 |
| Resistance Level | $45.76 | N/A |
| Average True Range (ATR) | 2.32 | 1.93 |
| MACD | 0.25 | 0.67 |
| Stochastic Oscillator | 58.76 | 96.28 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.